Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee advances bill to require coverage for FDA‑approved biomarker testing when medically necessary
Summary
The House Government Operations Committee advanced HB 484 after physician testimony that biomarker testing improves diagnosis and treatment selection. Lawmakers pressed on prior‑authorization timelines and whether genetic or biomarker results could affect insurance coverage; the committee voted 15–0 to move the bill to Finance and Ways and Means.
Representative Martin’s HB 484, which would require coverage of FDA‑approved biomarker tests when ordered by a provider and meeting medical necessity, advanced from the House Government Operations Committee following expert testimony and member questions.
Neurologist David Charles of Vanderbilt University, speaking for the nonprofit Alliance for Patient Access, told the committee biomarker testing lets clinicians “select the right therapy,” improving outcomes in cancer, rheumatology and neurology. He gave a personal example…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
